Ipamorelin: one dosing study, one failed surgical trial, and no human data on the popular blend

Ipamorelin does what it was designed to do: it makes the pituitary release a burst of growth hormone, in animals and in people [1,2]. Beyond that, the human evidence is two papers. One measured blood levels in healthy men in 1999 [2]; the other tested it after bowel surgery in 2014 and found no significant benefit over placebo [3]. The selectivity it is famous for comes from pig and rat studies, and the ipamorelin-plus-CJC-1295 blend has never been tested in a published human study.

What it is

Ipamorelin is a five-unit peptide made by Novo Nordisk in the 1990s: Aib-His-D-2-Nal-D-Phe-Lys-NH2 [1]. Only histidine and lysine are ordinary amino acids; the other three are synthetic or mirror-image building blocks the body does not make. It came out of a chemistry programme trimming down GHRP-1, one of the early synthetic growth hormone-releasing peptides [1].

It works on a different switch from CJC-1295 or sermorelin. Those mimic GHRH. Ipamorelin mimics ghrelin, acting on the growth hormone secretagogue receptor (the ghrelin receptor), which the pituitary and hypothalamus also use to trigger growth hormone release [1]. Stimulating ghrelin receptors also speeds movement through the gut, which is why ipamorelin was later tried as a treatment for a stalled bowel after surgery [3].

The selectivity claim, and where it comes from

The reason ipamorelin became popular is a single finding from its launch paper. Older growth hormone-releasing peptides such as GHRP-6 and GHRP-2 also raise the stress hormones ACTH and cortisol. In conscious pigs, ipamorelin did not raise ACTH or cortisol above what GHRH itself caused, even at doses more than 200 times the dose needed for half its growth hormone effect [1]. It also left FSH, LH, prolactin and TSH alone in those pigs [1].

That is a genuine and useful pharmacological result, and the concern it addresses is real in humans: in healthy men given the older peptide GHRP-6 intravenously, prolactin and cortisol roughly doubled at the highest dose tested [6]. But the ipamorelin result is a pig result. The published human study did not measure cortisol or prolactin [2], so the claim that ipamorelin spares cortisol in people is an extrapolation, not a finding.

The human evidence

Gobburu and colleagues, 1999: how it behaves in the blood

This is the only published study of ipamorelin in healthy people [2]. Forty healthy men took part, eight at each of five dose levels, and each received a 15-minute intravenous infusion. The researchers measured ipamorelin and growth hormone in the blood and built a model linking the two.

The drug behaved predictably: blood levels rose in proportion to dose, and the terminal half-life was about two hours [2]. Each infusion produced a single burst of growth hormone, peaking at about 40 minutes (0.67 hours) and then fading to negligible levels at every dose [2]. Individual responses varied more than drug levels did.

What the study tells you is that ipamorelin produces a short, single pulse rather than a sustained rise. That is the opposite profile to CJC-1295 with DAC, which keeps growth hormone raised for days [7], and it is one reason people pair the two. Whether a daily artificial pulse on top of the body’s own rhythm does anything useful for an adult with a normal pituitary is the question no trial has asked. What it does not tell you is anything about IGF-1 over time, body composition, sleep, or side effects with repeated use, because it did not look.

Beck and colleagues, 2014: the only randomised patient trial

Ipamorelin’s one real clinical test was in postoperative ileus, the temporary paralysis of the gut that can follow abdominal surgery [3]. The phase 2 trial randomised 117 adults having small or large bowel resection to intravenous ipamorelin (0.03 mg/kg twice daily) or placebo from the first day after surgery for up to seven days. The main measure was time to tolerating a standard solid meal.

The ipamorelin group tolerated food a median seven hours sooner, but the difference was not statistically significant (p = 0.15), and there were no significant differences on the secondary measures either [3]. The authors called the drug well tolerated. Treatment-emergent adverse events were common in both arms, as you would expect after major surgery: 87.5% on ipamorelin and 94.8% on placebo [3]. We found no later trial, and ipamorelin has not been approved for any use.

The trial did not measure growth hormone effects on muscle, fat or recovery, so it tells us nothing about the reasons most people take ipamorelin now.

What the animal work suggests

In rats, ipamorelin increased longitudinal bone growth [4]. In a rodent model of postoperative ileus it improved gastric emptying, which is why the surgical trial was attempted [5]. The fact that the rodent gut result did not clearly carry over to patients [3] is a useful reminder of how often that happens.

The blend question: ipamorelin with CJC-1295

Ipamorelin is most often sold premixed with CJC-1295, usually the “no DAC” form. The logic is real endocrinology. GHRH and the ghrelin-receptor agonists act through different receptors, and when both are given together the growth hormone response can exceed the sum of the two. That synergy was shown in healthy men in 1990, but with GHRP-6 and native GHRH given as single intravenous doses, not with ipamorelin or CJC-1295 [6].

For the actual combination, the evidence is absent. CJC-1295 has two human studies of its own, both of the long-acting DAC form, both from 2006, neither combined with anything [7]. A PubMed search in September 2026 for ipamorelin with CJC-1295 returned only review articles, no trials, and a 2026 clinical review of GH-axis peptides describes the combined “stacking practices” used online as a source of uncertainty rather than evidence [8]. So:

Synergy in a single-dose hormone test is a reasonable hypothesis for the blend. It is not proof of any benefit, and the amplified growth hormone signal is also the thing you would worry about for side effects.

Safety and side effects

The formal human safety record is short: 40 men given single infusions [2] and 114 surgical patients treated for up to a week [3]. Neither abstract reports a safety concern. The FDA, however, keeps ipamorelin acetate on its list of compounding substances that may present significant safety risks, noting that “a study published in literature identified serious adverse events including death” when ipamorelin was given intravenously for gastric motility [9]. The agency does not name the study on that page, and we could not match the statement to a specific published report.

The FDA also flags a risk of immune reactions from aggregation or impurities, notes that the unnatural amino acids complicate quality testing, and says it has no safety data for the injection routes people use outside trials [9]. A 2026 clinical review lists water retention, joint and muscle aches, changes in appetite, raised prolactin or cortisol, blood sugar changes and injection-site reactions among problems seen with GH-axis peptides as a group [8]. Nobody has measured how often any of these happen with ipamorelin specifically over months of use.

Legal and regulatory status

• US: not approved by the FDA for any use. It remains in category 2 of the FDA’s interim policy for outsourcing facilities (503B), while the nomination under the pharmacy-compounding route (503A) was withdrawn [9].
• UK: not licensed as a medicine.
• Sport: prohibited at all times. The 2026 WADA Prohibited List names ipamorelin under S2.2.4, growth hormone secretagogues [10].

What we still don’t know

• Whether ipamorelin changes body composition, sleep, recovery or anything else people take it for. No human trial has measured those outcomes.
• Whether the cortisol-sparing effect seen in pigs holds in humans.
• What subcutaneous dosing, the way it is actually used, does to growth hormone and IGF-1 over weeks.
• Anything at all about the ipamorelin and CJC-1295 blend in people.
• Which published report the FDA was referring to when it described a death.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR × Proper Protocols · Free · live online · with Q&A